Two years post-stealth ex­it, high­ly se­cre­tive in­flam­ma­tion biotech se­cures fi­nal tranche of Se­ries A round

Back in Sep­tem­ber 2020, a tiny biotech emerged from stealth out of Nashville, call­ing it­self Amytrx Ther­a­peu­tics and pur­su­ing chron­ic in­flam­ma­tion. By all mea­sures, the biotech has been ex­treme­ly qui­et — pub­lish­ing on­ly one press re­lease an­nounc­ing its stealth ex­it.

Now, it’s got its next one.

The biotech an­nounced Wednes­day that it closed the fi­nal tranche of its Se­ries A round, which to­tals $18 mil­lion to ex­pand on clin­i­cal re­search for AMTX-100, its an­ti-in­flam­ma­to­ry pep­tide drug can­di­date that is be­ing re­searched for a va­ri­ety of in­flam­ma­to­ry in­di­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER